Alzheimer's disease severity, objectively determined and measured

INTRODUCTION: With expansion of clinical trials to individuals across the spectrum of Alzheimer disease (AD) from preclinical to symptomatic phases, it is increasingly important to quantify AD severity using methods that capture underlying pathophysiology. METHODS: We derived an AD severity measure...

Descripción completa

Detalles Bibliográficos
Autores principales: Gross, Alden L., Mungas, Dan M., Leoutsakos, Jeannie-Marie S., Albert, Marilyn S., Jones, Richard N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Diagnostic Assessment & Prognosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078784/
https://www.ncbi.nlm.nih.gov/pubmed/27830173
http://dx.doi.org/10.1016/j.dadm.2016.08.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078784/
https://www.ncbi.nlm.nih.gov/pubmed/27830173
http://dx.doi.org/10.1016/j.dadm.2016.08.005

Ejemplares similares